The document discusses current practices for adjuvant melanoma treatment in the US. It finds that interferon is the primary adjuvant therapy offered, especially for stage III disease. While some patients receive observation or enroll in clinical trials, interferon usage increases with more advanced disease stages. No single reason dominates a physician's decision not to offer interferon adjuvant therapy. Adjuvant interferon usage is generally consistent across medical oncology, dermatology, radiation oncology and surgical oncology specialties and increases with more severe disease.